Qt Imaging Holdings, Inc. · NASDAQ:QTI
Qt Imaging — Investor Presentation (August 2026)
32 slides from Qt Imaging's investor presentation, Aug 12, 2026
Slide 1: Quantitative Transmission Imaging Breast Acoustic CT Scanner
Quantitative Transmission Imaging Breast Acoustic CT™ Scanner August 2026 NASDAQ:QTI Copyright ©2026 QT Imaging, Inc. All Rights Reserved.
Slide 2: Disclaimer: About This Presentation
2 Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the “Company”, “QT Imaging Holdings”, “QTI”), nor its respec
Slide 3: Disclaimer: Forward Looking Statements
3 Disclaimer FORWARD LOOKING STATEMENTS Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements genera
Slide 4: Our Mission: Transforming Breast Health For Every Woman
4 Our Mission Transforming Breast Health For Every Woman At QT Imaging, we are redefining what’s possible in breast imaging - delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short. Our goal is to replace outdated breast imaging workflows with the fi
Slide 5: QT Imaging Transformation timeline 2012-2026
5 $18M from NIH to develop supplemental imaging modality to resolve dense breasts 2012-2025 QT Imaging Transformation Company founded by John Klock, MD 2012 FDA Clearance 2017 Raise $18M PIPE Oct 2025 $10M Underwritten Public Offering May 2026 QTI becomes public on NASDAQ Mar 2024 Approval of Reimbu
Slide 6: The Pain and Why QT Imaging
6 The Pain and Why QT Imaging The Pain Why QT Imaging Copyright ©2026 QT Imaging, Inc. All Rights Reserved • Mammography misses cancers in dense breasts / it is painful • MRI is expensive / slow / uncomfortable / contrast injection • Ultrasound is operator dependent • Workflow is fragmented • High a
Slide 7: Today's Challenge vs QT Imaging Solution in screening
7 Primary Screening Today’s Challenge: Multi-step, patient anxiety and attrition prone process with high number of unnecessary biopsies Accurate Imaging for Dense Breasts Breast Density Confirmation Supplemental Screening QT Imaging Solution: Single step (Supplemental + Dx) patient friendly process,
Slide 8: QT Imaging Value Proposition
8 QT Imaging Value Proposition • One-stop-shop supplemental + diagnostic imaging • No radiation, no compression, no contrast • Low recall, less anxiety • Operator independent • One test – multiple results (MRI like Imaging) • Calcium visualization (DCIS + Ca, Density, Doubling, Cyst/Solid, Implant)
Slide 9: Our Technology and Product
9 Reflection transducers Transmission mode receiver Transmission mode transmitter Our Technology and Product • FDA-cleared, patent protected breast imaging modality • Pain free, safe, no radiation or contrast • Inherently 3D quantitative, imaging modality, thus it’s high resolution, similar to MRI •
Slide 10: Optimized Patient Experience
10 Optimized Patient Experience •No ionizing radiation. Acoustic source only •No breast compression and associated discomfort • 10-12 minutes per breast exam time •Quiet and comfortable (compared to MRI – claustrophobia, coil pressure, noise, lengthy exams) •No contrast injection or associated risk
Slide 11: Our Market, Why Now, and How It Fits In
Our Market, Why Now, and How It Fits In
Slide 12: QT Imaging's Technology Has the Opportunity to Transform the Breast Imaging Market
12 (1) https://www.futuremarketinsights.com/reports/automated-breast-ultrasound-system-market (2) https://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market $5.45B for 2024 with 8.9% CAGR. (3) https://www.archivemarketresearch.com/reports/breast-cancer-biomarkers-316622 (4)
Slide 13: Three Tailwinds Positioning QT Imaging for Growth
13Copyright ©2026 QT Imaging, Inc. All Rights Reserved. | NOT FOR PUBLIC DISTRIBUTION The FDA Has Recognized the Importance of Breast Density in Breast Cancer Screening Radiology is the leading specialty for clinical AI adoption • ~30 to 48% of radiologists report active clinical AI use; adoption co
Slide 14: Breast Cancer Screening Matrix: QT Imaging Sweet Spot
14 Breast Cancer Screening Matrix: QT Imaging Sweet Spot Risk Category (Tyrer-Cuzick Lifetime Risk) + Breast Density Typical Risk Profile Description < 40 Years ≥ 40 Years Low Risk (<12%) (~20–30% of women) No first-degree relatives with breast cancer No known pathogenic mutations No prior chest rad
Slide 15: Validation
%. -> QT IMAGING Validation
Slide 16: Clinical Advisory Board
16 Clinical Advisory Board Copyright ©2026 QT Imaging, Inc. All Rights Reserved Dr. Mary Yamashita, MD Dr. Barry Roseman, MD, FACS Dr. John Tentinger Section Chief of Breast Imaging at USC's Keck School of Medicine and a longtime leader in breast cancer screening research, Dr. Yamashita advises QT I
Slide 17: Growing Global Validation
17 Growing Global Validation • Existing FDA clearance to offer an imaging modality for all patients above 18 years old •Received Saudi Arabia, UAE, and Israel regulatory approvals •NIH $18M funding to generate a safe imaging modality for women with dense breasts •Ongoing clinical studies at: −Mayo C
Slide 18: Clinical Validation: Mayo Clinic - QT Scan vs MRI
18 Clinical Validation Across Screening & Oncology Applications: Mayo Clinic – QT Scan vs MRI • Mayo Clinic prospective feasibility study: 26 high-risk women comparing QT Imaging (QT Scan) with breast MRI for supplemental screening • Strong breast-level agreement with MRI: binary agreement between Q
Slide 19: Clinical Validation: Sunnybrook Cancer Center - QT Scan vs MRI
19 MRI Clinical Validation Across Screening & Oncology Applications: Sunnybrook Cancer Center – QT Scan vs MRI • NIH/NCI-funded, to prove QT Imaging as imaging modality for early monitoring of breast cancer response to neoadjuvant chemotherapy (NAC) • Major oncology need: − treatment response that c
Slide 20: Multi-site Repeatability & Reproducibility Study
20Copyright ©2026 QT Imaging, Inc. All Rights Reserved. Multi-site Repeatability & Reproducibility Study • Multi-site study (2 sites, 5 patients/site, 5 scans each) confirms QT Imaging's quantitative biomarkers are highly reproducible within and across scanners • Speed of Sound (SoS), our core tissu
Slide 21: Expanded Global Regulatory Foundation
21Copyright ©2026 QT Imaging, Inc. All Rights Reserved. | NOT FOR PUBLIC DISTRIBUTION Expanded Global Regulatory Foundation Saudi FDA (SFDA) UAE (MOHAP) Submitted Dossier Feb, 2026 Authorized Rep via Gulf Medical; MDS-GS-004 Under SFDA Regulatory Review Approved June 2026 Dossier Preparation Leverag
Slide 22: Business Model, Partnerships & Financial Trajectory
Business Model, Partnerships & Financial Trajectory
Slide 23: Business Model: HW + SaaS + AI Diagnostic Layer
23 Business Model HW+ SaaS +AI Diagnostic Layer Business Model: • Hardware sale (scanner): upfront revenue • SaaS platform: recurring revenue • AI diagnostic layer: higher margin Radiology Cloud SaaS Platform Referring MD Hardware gets us in the door. Software builds the company. Copyright ©2026 QT
Slide 24: Planned Evolution to Hybrid Commercial Model as Scale Increases
24 Planned Evolution to Hybrid Commercial Model as Scale Increases Commercial strategy balances capital efficiency today with increasing control and margin expansion over time. 2024-2026 2027 and beyond Distributor Led Hybrid Model • Broad market coverage • Capital efficient • Rapid deployment • Dir
Slide 25: Business Partnerships Today
25Copyright ©2026 QT Imaging, Inc. All Rights Reserved. Business Partnerships Today Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S. market Under Distribution Agreement with Gulf Medical for Kingdom of Saudi Arabia (KSA) market Under Distribution Agreement
Slide 26: QTI Precision Pathway - Cloud SaaS Platform
26 QTI Precision Pathway – Cloud SaaS Platform Core Operational Advanced Enterprise System software updates Long term technology relevance Collaboration & data sharing Quantitated biomarkers Automated analysis Precision reporting Multiuser access Enterprise collaboration Scanner Evergreen QTI Precis
Slide 27: Financial Trajectory: Revenue and Scanner Shipments
27 Financial Trajectory $4.9 $18.9 $39.0 0 10 20 30 40 50 60 70 80 90 $- $5.0 $10.0 $15 .0 $20.0 $25.0 $30.0 $35.0 $40.0 $45.0 FY 2 024 A FY 2 025 A FY 2 026 F S h ip m e n ts ( # ) R e ve n u e ( $ M ) Yearly Revenue and Scanner Shipments Revenue ($M) Shipments (# ) FY-2024A FY-2025A FY-2026E CAGR
Slide 28: Financial Trajectory: Scaling a Commercial Business
28 Financial Trajectory QT Imaging is scaling a commercial business $407 $473 $488 $(613) $(88) $8 54% 45% 45% -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% $(700) $(600) $(500) $(400) $(300) $(200) $(100) $- $100 $200 $300 $400 $500 $600 FY 2024 A FY 2025 A FY 2026 F Revenue/scanner, Gross Marg
Slide 29: Manufacturing Capacity, Quality, and Compliance
29 Manufacturing Capacity, Quality, and Compliance • Expanded manufacturing capacity while improving operating efficiency − 22,000-square-foot headquarters and manufacturing facility − The expanded facility provides more than 2.5x the operational space of the current location while reducing lease co
Slide 30: Building a Multi-Generational Voice for Breast Health Awareness
30Copyright ©2026 QT Imaging, Inc. All Rights Reserved. | NOT FOR PUBLIC DISTRIBUTION Multi-Generational Reach • QTI is engaging with The Shift, a media platform reaching women across generations • At Wimbledon and Harvard forums, Dr. Dinu joined leaders spotlighting breast density awareness • The t
Slide 31: Executing on Early Commercial Scale With Near Term Value Inflection Points
31 QT Imaging Is Executing on Its Early Commercial Scale With Multiple Near Term Value Inflection Points • FDA-cleared and commercially validated technology, established regulatory foundation with growing clinical adoption • Commercial infrastructure in place through manufacturing, distribution, and
Slide 32: Thank You!
%. -> QT IMAGING Thank You!
QT Imaging Holdings — Investor Presentation (August 2026) on 6ix